Bruno Catalanotti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6000120/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Specific Targeting of Acetylcholinesterase and Butyrylcholinesterase Recognition Sites. Rational Design of Novel, Selective, and Highly Potent Cholinesterase Inhibitors. Journal of Medicinal Chemistry, 2003, 46, 1-4.	2.9	157
2	Non-Nucleoside HIV-1 Reverse Transcriptase (RT) Inhibitors: Past, Present, and Future Perspectives. Current Pharmaceutical Design, 2002, 8, 615-657.	0.9	124
3	Synthesis and Pharmacological Evaluation of Potent and Highly Selective D3 Receptor Ligands: Inhibition of Cocaine-Seeking Behavior and the Role of Dopamine D3/D2 Receptors. Journal of Medicinal Chemistry, 2003, 46, 3822-3839.	2.9	90
4	Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain. Frontiers in Chemistry, 2020, 8, 572885.	1.8	76
5	Endoperoxide Derivatives from Marine Organisms:  1,2-Dioxanes of the Plakortin Family as Novel Antimalarial Agents. Journal of Medicinal Chemistry, 2006, 49, 7088-7094.	2.9	66
6	Development of Molecular Probes for the Identification of Extra Interaction Sites in the Mid-Gorge and Peripheral Sites of Butyrylcholinesterase (BuChE). Rational Design of Novel, Selective, and Highly Potent BuChE Inhibitorsâ€. Journal of Medicinal Chemistry, 2005, 48, 1919-1929.	2.9	65
7	Pyrrolo[1,3]benzothiazepine-Based Serotonin and Dopamine Receptor Antagonists. Molecular Modeling, Further Structureâ^'Activity Relationship Studies, and Identification of Novel Atypical Antipsychotic Agents. Journal of Medicinal Chemistry, 2004, 47, 143-157.	2.9	60
8	Exploiting Protein Fluctuations at the Active-Site Gorge of Human Cholinesterases: Further Optimization of the Design Strategy to Develop Extremely Potent Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 3154-3170.	2.9	56
9	A Rational Approach to the Design of Selective Substrates and Potent Nontransportable Inhibitors of the Excitatory Amino Acid Transporter EAAC1 (EAAT3). New Glutamate and Aspartate Analogues as Potential Neuroprotective Agents. Journal of Medicinal Chemistry, 2001, 44, 2507-2510.	2.9	54
10	Pyrrolo[1,5]benzoxa(thia)zepines as a New Class of Potent Apoptotic Agents. Biological Studies and Identification of an Intracellular Location of Their Drug Target. Journal of Medicinal Chemistry, 2005, 48, 4367-4377.	2.9	53
11	Discovery of Huperzine Aâ^'Tacrine Hybrids as Potent Inhibitors of Human Cholinesterases Targeting Their Midgorge Recognition Sites. Journal of Medicinal Chemistry, 2006, 49, 3421-3425.	2.9	50
12	Benzoxepin-Derived Estrogen Receptor Modulators:Â A Novel Molecular Scaffold for the Estrogen Receptor. Journal of Medicinal Chemistry, 2004, 47, 5612-5615.	2.9	48
13	Neuronal High-Affinity Sodium-Dependent Glutamate Transporters (EAATs): Targets for the Development of Novel Therapeutics Against Neurodegenerative Diseases. Current Pharmaceutical Design, 2003, 9, 599-625.	0.9	47
14	Targeting G-Quadruplex Structure in the Human c-Kit Promoter with Short PNA Sequences. Bioconjugate Chemistry, 2011, 22, 654-663.	1.8	45
15	Exploitation of a Very Small Peptide Nucleic Acid as a New Inhibitor of miR-509-3p Involved in the Regulation of Cystic Fibrosis Disease-Gene Expression. BioMed Research International, 2014, 2014, 1-10.	0.9	45
16	Specific Targeting Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. Design, Synthesis, and Biological Evaluation of Novel, Potent, and Broad Spectrum NNRTIs with Antiviral Activity. Journal of Medicinal Chemistry, 2005, 48, 7153-7165.	2.9	43
17	Design and Synthesis of Potent Antimalarial Agents Based on Clotrimazole Scaffold:Â Exploring an Innovative Pharmacophore. Journal of Medicinal Chemistry, 2007, 50, 595-598.	2.9	40
18	Insight into the mechanism of action of plakortins, simple 1,2-dioxaneantimalarials. Organic and Biomolecular Chemistry, 2010, 8, 846-856.	1.5	39

#	Article	IF	CITATIONS
19	Specific Targeting of Peripheral Serotonin 5-HT ₃ Receptors. Synthesis, Biological Investigation, and Structureâ^Activity Relationships. Journal of Medicinal Chemistry, 2009, 52, 3548-3562.	2.9	38
20	Novel Atypical Antipsychotic Agents:Â Rational Design, an Efficient Palladium-Catalyzed Route, and Pharmacological Studies. Journal of Medicinal Chemistry, 2005, 48, 1705-1708.	2.9	37
21	Pyrrolo[1,3]benzothiazepine-Based Atypical Antipsychotic Agents. Synthesis, Structureâ^'Activity Relationship, Molecular Modeling, and Biological Studies. Journal of Medicinal Chemistry, 2002, 45, 344-359.	2.9	36
22	Synthesis of N-1 and ribose modified inosine analogues on solid support. Tetrahedron Letters, 2007, 48, 397-400.	0.7	34
23	Synthesis of 4-N-alkyl and ribose-modified AICAR analogues on solid support. Tetrahedron, 2008, 64, 6475-6481.	1.0	34
24	Synthesis and biological evaluation of unprecedented ring-expanded nucleosides (RENs) containing the imidazo[4,5-d][1,2,6]oxadiazepine ring system. Chemical Communications, 2012, 48, 9310.	2.2	33
25	Synthesis of quadruplexâ€forming tetraâ€endâ€linked oligonucleotides: Effects of the linker size on quadruplex topology and stability. Biopolymers, 2009, 91, 466-477.	1.2	31
26	Facile Solidâ€Phase Synthesis of AICAR 5′â€Monophosphate (ZMP) and Its 4â€≺i>Nâ€Alkyl Derivatives. European Journal of Organic Chemistry, 2010, 2010, 1517-1524.	1.2	31
27	A solid-phase approach to the synthesis of N-1-alkyl analogues of cyclic inosine-diphosphate-ribose (cIDPR). Tetrahedron, 2010, 66, 1931-1936.	1.0	30
28	A Facile Synthesis of 5'-Fluoro-5'-deoxyacadesine (5'-F-AICAR): A Novel Non-phosphorylable AICAR Analogue. Molecules, 2012, 17, 13036-13044.	1.7	30
29	Hyodeoxycholic acid derivatives as liver X receptor α and G-protein-coupled bile acid receptor agonists. Scientific Reports, 2017, 7, 43290.	1.6	30
30	Peptide Nucleic Acids as miRNA Target Protectors for the Treatment of Cystic Fibrosis. Molecules, 2017, 22, 1144.	1.7	29
31	Feedback inhibition of cAMP effector signaling by a chaperone-assisted ubiquitin system. Nature Communications, 2019, 10, 2572.	5.8	29
32	G-Quadruplex-Forming Oligonucleotide Conjugated to Magnetic Nanoparticles: Synthesis, Characterization, and Enzymatic Stability Assays. Bioconjugate Chemistry, 2012, 23, 382-391.	1.8	27
33	Peptide Nucleic Acid-Functionalized Adenoviral Vectors Targeting G-Quadruplexes in the P1 Promoter of Bcl-2 Proto-Oncogene: A New Tool for Gene Modulation in Anticancer Therapy. Bioconjugate Chemistry, 2019, 30, 572-582.	1.8	25
34	Synthesis and Triple Helix Formation by Alternate Strand Recognition of Oligonucleotides Containing 3â€~-3â€~ Phosphodiester Bonds. Journal of Organic Chemistry, 1997, 62, 9024-9030.	1.7	20
35	Substrate inhibitors and blockers of excitatory amino acid transporters in the treatment of neurodegeneration: critical considerations. European Journal of Pharmacology, 2003, 479, 291-296.	1.7	18
36	Development of piperazine-tethered heterodimers as potent antimalarials against chloroquine-resistant P. falciparum strains. Synthesis and molecular modeling. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3535-3539.	1.0	18

BRUNO CATALANOTTI

#	Article	IF	CITATIONS
37	Synthesis, self-assembly-behavior and biomolecular recognition properties of thyminyl dipeptides. Arabian Journal of Chemistry, 2020, 13, 1966-1974.	2.3	18
38	Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction. Biochemical Pharmacology, 2021, 188, 114564.	2.0	18
39	2′-deoxy-8-(propyn-1-yl)adenosine-containing oligonucleotides: effects on stability of duplex and quadruplex structures. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2005-2009.	1.0	17
40	Synthesis and characterization of new 3′-3′ linked oligodeoxyribonucleotides for alternate strand triple helix formation. Tetrahedron, 1999, 55, 9899-9914.	1.0	16
41	Full relative stereochemistry assignment and conformational analysis of 13,19-didesmethyl spirolide C via NMR- and molecular modeling-based techniques. A step towards understanding spirolide's mechanism of action. Organic and Biomolecular Chemistry, 2009, 7, 3674.	1.5	16
42	Design, synthesis and biochemical investigation, by in vitro luciferase reporter system, of peptide nucleic acids as new inhibitors of miR-509-3p involved in the regulation of cystic fibrosis disease-gene expression. MedChemComm, 2014, 5, 68-71.	3.5	16
43	Synthesis of a New N1-Pentyl Analogue of Cyclic Inosine Diphosphate Ribose (clDPR) as a Stable Potential Mimic of Cyclic ADP Ribose (cADPR). European Journal of Organic Chemistry, 2002, 2002, 4234-4238.	1.2	15
44	Targeting multiple G-quadruplex–forming DNA sequences: Design, biophysical and biological evaluations of indolo-naphthyridine scaffold derivatives. European Journal of Medicinal Chemistry, 2019, 182, 111627.	2.6	15
45	The TBC1D31/praja2 complex controls primary ciliogenesis through PKAâ€directed OFD1 ubiquitylation. EMBO Journal, 2021, 40, e106503.	3.5	15
46	Discovery of Bile Acid Derivatives as Potent ACE2 Activators by Virtual Screening and Essential Dynamics. Journal of Chemical Information and Modeling, 2022, 62, 196-209.	2.5	15
47	Synthetic studies on the glycosylation of the base residues of inosine and uridine. Journal of the Chemical Society Perkin Transactions 1, 1999, , 3489-3493.	0.9	13
48	Circular dichroism and thermal melting differentiation of Hoechst 33258 binding to the curved (A4T4) and straight (T4A4) DNA sequences. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2002, 1576, 136-142.	2.4	13
49	Synthesis of New Acadesine (AICA-riboside) Analogues Having Acyclic d-Ribityl or 4-Hydroxybutyl Chains in Place of the Ribose. Molecules, 2013, 18, 9420-9431.	1.7	12
50	Interaction of the N-(3-Methylpyridin-2-yl)amide Derivatives of Flurbiprofen and Ibuprofen with FAAH: Enantiomeric Selectivity and Binding Mode. PLoS ONE, 2015, 10, e0142711.	1.1	12
51	Novel propanamides as fatty acid amide hydrolase inhibitors. European Journal of Medicinal Chemistry, 2017, 136, 523-542.	2.6	10
52	Synthesis and Biological Evaluation of a New Structural Simplified Analogue of cADPR, a Calcium-Mobilizing Secondary Messenger Firstly Isolated from Sea Urchin Eggs. Marine Drugs, 2018, 16, 89.	2.2	10
53	PNA-Based Graphene Oxide/Porous Silicon Hybrid Biosensor: Towards a Label-Free Optical Assay for Brugada Syndrome. Nanomaterials, 2020, 10, 2233.	1.9	10
54	Syntheses of [1-15N]-2′-Deoxyinosine, [4-15N]-2′-DeoxyAICAR, and [1-15N]-2′-Deoxyguanosine. Europe Journal of Organic Chemistry, 1999, 1999, 2235-2239.	an 1.2	9

4

BRUNO CATALANOTTI

#	Article	IF	CITATIONS
55	PNA as a potential modulator of COL7A1 gene expression in dominant dystrophic epidermolysis bullosa: a physico-chemical study. Molecular BioSystems, 2013, 9, 3166.	2.9	9
56	Exploring the fatty acid amide hydrolase and cyclooxygenase inhibitory properties of novel amide derivatives of ibuprofen. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 815-823.	2.5	9
57	GLP-1 Mediates Regulation of Colonic ACE2 Expression by the Bile Acid Receptor GPBAR1 in Inflammation. Cells, 2022, 11, 1187.	1.8	9
58	Synthesis and label free characterization of a bimolecular PNA homo quadruplex. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1222-1228.	1.1	8
59	Structural Model of the hUbA1-UbcH10 Quaternary Complex: In Silico and Experimental Analysis of the Protein-Protein Interactions between E1, E2 and Ubiquitin. PLoS ONE, 2014, 9, e112082.	1.1	7
60	New Linear Precursors of cIDPR Derivatives as Stable Analogs of cADPR: A Potent Second Messenger with Ca2+-Modulating Activity Isolated from Sea Urchin Eggs. Marine Drugs, 2019, 17, 476.	2.2	6
61	Benzylamides and piperazinoarylamides of ibuprofen as fatty acid amide hydrolase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 562-576.	2.5	6
62	Probing the DNA Reactivity and the Anticancer Properties of a Novel Tubercidin-Pt(II) Complex. Pharmaceutics, 2020, 12, 627.	2.0	6
63	Exploring a peptide nucleic acid-based antisense approach for CD5 targeting in chronic lymphocytic leukemia. PLoS ONE, 2022, 17, e0266090.	1.1	5
64	SYNTHESIS OF 5-METHYLAMINO-2′-DEOXYURIDINE DERIVATIVES. Nucleosides, Nucleotides and Nucleic Acids, 2001, 20, 1831-1841.	0.4	4
65	SYNTHESIS OF A NEW N-9 RIBITYL ANALOGUE OF CYCLIC INOSINE DIPHOSPHATE RIBOSE (cIDPR) AS A MIMIC OF CYCLIC ADP RIBOSE (cADPR). Nucleosides, Nucleotides and Nucleic Acids, 2005, 24, 735-738.	0.4	4
66	Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease. Frontiers in Pharmacology, 2022, 13, 858137.	1.6	4
67	Oligonucleotides Containing an Acridine Group Covalently Bonded to the Nucleotide Flanking the 3′-3′ Phosphodiester Junction for Alternate Strand Triple Helix Formation. Nucleosides, Nucleotides and Nucleic Acids, 2003, 22, 1069-1071.	0.4	3
68	Design, synthesis and <i>inÂvitro</i> and <i>inÂvivo</i> biological evaluation of flurbiprofen amides as new fatty acid amide hydrolase/cyclooxygenase-2 dual inhibitory potential analgesic agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 940-953.	2.5	3
69	Structural Basis for Developing Multitarget Compounds Acting on Cysteinyl Leukotriene Receptor 1 and G-Protein-Coupled Bile Acid Receptor 1. Journal of Medicinal Chemistry, 2021, 64, 16512-16529.	2.9	3